Search results
Showing 766 to 780 of 1244 results for pathway
The NICE public health guidance development process (third edition) (PMG5)
The NICE public health guidance development process (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection
- 3 The guidance development processes
- 4 The role of stakeholders in the guidance development process
- 5 The role of the Public Health Advisory Committees (PHACs) in the development of public health guidance
- 6 The role of evidence providers
- 7 The role of the CPHE project team
- 8 Fieldwork
The social care guidance manual
Show all sections
- 1 Introduction
- 2 The scope
- 3 The Guidance Development Group
- 4 Developing review questions and planning the systematic review
- 5 Identifying the evidence: literature searching and evidence submission
- 6 Reviewing the evidence
- 7 Incorporating economic evaluation
- 8 Linking social care guidance to other NICE guidance
NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .
Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack
psychopathology scores, were more likely to progress through the rehabilitation pathway to greater independence. However, the committee...
NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .
NICE has developed a medtech innovation briefing (MIB) on Colli-Pee for first void urine collection .
NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .
MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)
NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection .
Janus kinase (JAK) inhibitors, and target a different part of the immune pathway. This means that people who either cannot tolerate...
Following the successful evaluation of Zio XT, developers of digital health technologies are encouraged to engage with NICE through one of several different routes.
maternal risk factors, neonatal needs, and stage of the maternity care pathway). - Environmental factors (for example, local geography...
The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)
Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.
Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.